Top 10 Performing Stocks To Watch For 2023


Humana Inc. (HUM Quick QuoteHUM ) formed an alliance with Curant Health for enhancing the health experiences of Humana members who are suffering Chronic Heart Failure and Chronic Obstructive Pulmonary Disease.

This new pilot program intends to increase medication adherence to enable patients to lead better lives as well as decrease medical expenses.

Humana members with complicated health conditions will now leverage comprehensive support from this unique tie-up. Curant Health is a Medication Care Management organization with expertise in high-touch clinical aid for patients with chronic conditions.

This deal focuses on curbing adverse drug reactions, thereby lowering the need for hospital admissions. Both companies are committed to offer a better member experience.

This only helps the company utilize Curant Health’s innovative approach to customize patient care and data-driven insights that eventually facilitates the intake of prescription medicines.


This is not the first time that the health insurer took steps to ensure patient safety.

In July, Humana entered into a multi-year tie-up with Montefiore, one of New York’s premier academic health systems, to provide its Medicare Advantage members with access to the health system’s in-network medical care. The leading health insurer forged this partnership to widen the availability of the top-notch healthcare facilities among its current and future members.

In a year’s time, the stock has gained 5.8%, underperforming its industry’s growth of 33.2%. However, its series of acquisitions and dispositions, efficient capital deployment and a strong Medicare business position it for long-term gains. The company’s Medicaid business has also been contributing to its top line for years now on the back of contract wins.

Top 10 Performing Stocks To Watch For 2023: Cytosorbents Corporation(CTSO)


CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications; the prevention of post-operative complications of cardiopulmonary bypass surgery and damage to organs donated by brain-dead donors prior to organ harvest; the treatment of cancer cachexia; and the prevention of transfusion reactions caused by contaminants in transfused blood products; and the prevention of contrast induced nephropathy, the treatment of drug overdose, and the treatment of chronic kidney failure. The company is also developing HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.


Advisors’ Opinion:

  • [By Stephan Byrd]

    Innova (CURRENCY:INN) traded 3.2% lower against the dollar during the 24 hour period ending at 15:00 PM E.T. on February 16th. One Innova coin can now be bought for approximately $0.0145 or 0.00000399 BTC on exchanges. Innova has a total market capitalization of $73,312.00 and approximately $50.00 worth of Innova was traded on exchanges in the last 24 hours. Over the last week, Innova has traded down 19.6% against the dollar.

  • [By Logan Wallace]

    COPYRIGHT VIOLATION WARNING: “Summit Hotel Properties Inc (INN) to Issue Quarterly Dividend of $0.18” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at www.tickerreport.com/banking-finance/4125733/summit-hotel-properties-inc-inn-to-issue-quarterly-dividend-of-0-18.html.

  • [By Logan Wallace]

    Municipal Employees Retirement System of Michigan trimmed its stake in shares of Summit Hotel Properties Inc (NYSE:INN) by 29.1% during the second quarter, HoldingsChannel reports. The firm owned 29,520 shares of the real estate investment trust’s stock after selling 12,110 shares during the period. Municipal Employees Retirement System of Michigan’s holdings in Summit Hotel Properties were worth $422,000 at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Summit Hotel Properties (INN)


    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Performing Stocks To Watch For 2023: Sinovac Biotech Ltd.(SVA)

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against the hepatitis A, hepatitis B, and influenza viruses in the People’s Republic of China. It offers Healive, an inactivated hepatitis A vaccine; Bilive, a combination of hepatitis A and B vaccine; Anflu, a split virus influenza vaccine; and Panflu, a vaccine against the influenza A H1N1 virus. The company’s pipeline vaccine candidates include a split viron vaccine, which completed Phase II clinical trials for the H5N1 influenza virus; and a SARS vaccine, which completed Phase I clinical trials for the SARS virus. In addition, its pipeline vaccine candidates that completed the pre-clinical trials comprise human vaccines for EV71, pneumococcal conjugate, haemophilus influenzae type b, meningitis, Japanese encephalitis, chickenpox, mumps, and rubella diseases, as well as rabies vaccine for humans and animals. The company markets and sell s its vaccine products directly to the provincial and municipal disease control and prevention centers. It has a patent license agreement with the National Institutes of Health; distribution agreements with LG Life Sciences, Ltd. and Glovax C.V.; and a pandemic influenza vaccine co-development agreement with the China Center for Disease Control and Prevention. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People’s Republic of China.


Advisors’ Opinion:

  • [By Joseph Griffin]

    News articles about Sinovac Biotech (NASDAQ:SVA) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sinovac Biotech earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.8977999719642 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Top 10 Performing Stocks To Watch For 2023: Surgery Partners, Inc.(SGRY)


Surgery Partners, Inc., together with its subsidiaries, operates surgical facilities in the United States. The company operates through Surgical Facility Services, Ancillary Services, and Optical Services segments. Its surgical facilities include ambulatory surgery centers and surgical hospitals that provide non-emergency surgical procedures in various specialties, including gastrointestinal, general surgery, ophthalmology, orthopedics, cardiology, pain management, obstetrics/gynecology, plastic surgery, podiatry, neurology, and urology, as well as ear, nose, and throat. The company’s surgical hospitals also provide acute care services, such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and a suite of ancillary services that comprised of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services, and specialty pharmacy services. Surgery Partners, Inc. also operates optical laboratory that manufactures eyewear. As of August 17, 2015, it owned and operated a national network of 99 surgical facilities, which include 94 ambulatory surgery centers and 5 surgical hospitals in 28 states. Surgery Partners, Inc. was founded in 2004 and is based in Nashville, Tennessee.


Advisors’ Opinion:

  • [By Logan Wallace]

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI) CEO Adelene Q. Perkins sold 5,000 shares of Infinity Pharmaceuticals stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $2.82, for a total transaction of $14,100.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

  • [By Chris Lange]

    Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares made a healthy gain early on Tuesday after the firm announced a collaboration with Arcus Biosciences Inc. (NYSE: RCUS). These two companies have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types that typically show minimal response to checkpoint inhibition monotherapy.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Performing Stocks To Watch For 2023: Lyon William Homes(WLH)

William Lyon Homes, together with its subsidiaries, designs, constructs, markets, and sells single-family detached and attached homes in California, Arizona, Nevada, Colorado, Washington, and Oregon. The company sells its homes primarily to entry-level, first-time move-up and second-time move-up homebuyers under the Village Homes and Polygon Northwest Homes brands through in-house commissioned sales personnel and outside brokers. As of December 31, 2015, the company owned approximately 13,479 lots; and had options to purchase an additional 3,935 lots. William Lyon Homes was founded in 1954 and is headquartered in Newport Beach, California.

Leave a Reply

Your email address will not be published.